New weight loss drugs coming to the UK: 2026 pipeline tracker
The weight management drug pipeline is the most active it has ever been. Beyond the drugs already approved in the UK (Wegovy injection, Mounjaro, Saxenda, Orlistat, the Wegovy tablet), a series of next-generation treatments are in late-stage development or early commercialisation. This page tracks every significant drug in the pipeline, with current regulatory status, trial data and expected UK timeline.
We update this page when material regulatory or clinical developments occur. Get pipeline update alerts →
Pipeline drug status table — June 2026
| Drug | Generic name | Company | Type | UK status | Phase 2/3 weight loss |
|---|---|---|---|---|---|
| Wegovy tablet | Oral semaglutide | Novo Nordisk | GLP-1 oral tablet | ✅ Approved — pre-order live | ~15% at 68 weeks |
| Retatrutide | LY3437943 | Eli Lilly | Triple GLP-1/GIP/glucagon injection | ⏳ Phase 3 complete — pending MHRA | ~24% at 48 weeks (Ph2) |
| Orforglipron | Orforglipron | Eli Lilly | Oral GLP-1 (small molecule) | ⏳ Pending MHRA approval | ~15% at 36 weeks (Ph3) |
| Amycretin | Oral amycretin | Novo Nordisk | GLP-1/amylin oral tablet | 🔬 Phase 2 | ~22% at 36 weeks (Ph2) |
| CagriSema | Cagrilintide + semaglutide | Novo Nordisk | GLP-1/amylin injection | 🔬 Phase 3 | ~22.7% at 68 weeks (Ph3) |
| Mazdutide | Mazdutide | Innovent/Roche | GLP-1/glucagon injection | 🔬 Phase 3 (China/global) | ~15% at 24 weeks (Ph3) |
The drugs in detail
Retatrutide — triple agonist injection from Eli Lilly
The most anticipated drug in the current pipeline. Phase 2 data showed up to 24.2% weight reduction at 48 weeks — higher than any previously approved drug at equivalent timepoints. Phase 3 TRIUMPH trial data were reported in 2025. Not yet MHRA-approved. Weekly subcutaneous injection, not an oral tablet.
Full retatrutide UK guide → | When will it be available? →
Orforglipron — oral GLP-1 from Eli Lilly
A small-molecule oral GLP-1 agonist that, unlike the Wegovy tablet, does not require fasting before taking. Phase 3 OPAL trial data showed approximately 15% weight reduction. FDA review ongoing as of June 2026. MHRA approval in the UK has not been confirmed. If approved, it would be the second oral weight management tablet available in the UK.
Full orforglipron UK guide → | When will it be available? →
Amycretin — dual oral tablet from Novo Nordisk
Amycretin combines a GLP-1 agonist with amylin receptor activation in a single oral molecule. Phase 2 data presented in 2024 showed approximately 22% weight reduction at 36 weeks — striking for an oral drug. It is earlier in development than retatrutide or orforglipron but represents Novo Nordisk’s next-generation oral pipeline. No phase 3 data or regulatory submission timeline published as of June 2026.
CagriSema — dual injection from Novo Nordisk
CagriSema is a fixed-dose combination of cagrilintide (an amylin analogue) and semaglutide. Phase 3 REDEFINE trial data showed approximately 22.7% weight reduction at 68 weeks. This is an injection, not a tablet. It is positioned as a higher-efficacy injectable option, potentially bridging the gap to retatrutide-level outcomes for patients on an injectable pathway. MHRA submission status not yet confirmed.
The pattern: every generation is more effective
Looking at the data across generations, each new drug class appears to produce higher percentage weight loss:
- First-gen GLP-1 alone (liraglutide/Saxenda): ~8% at 56 weeks
- Semaglutide injection (Wegovy): ~15% at 68 weeks
- Oral semaglutide tablet (Wegovy tablet): ~15% at 68 weeks
- Tirzepatide/Mounjaro (dual GLP-1/GIP): ~22% at 72 weeks
- Retatrutide (triple agonist): ~24% at 48 weeks (phase 2)
- Amycretin (oral): ~22% at 36 weeks (phase 2)
This pattern is one reason why some patients are considering waiting for the next-generation drugs. But regulatory timelines are uncertain — a drug could be 12 months away or three years away — and treatment delay has its own costs.
Should I wait for a better drug or start now?
This is a genuine clinical question and the answer depends on your circumstances. Key considerations:
- Treatment delay has costs: Obesity carries health risks. Waiting one to three years for a drug that may or may not arrive on schedule means additional time without treatment.
- Switching is possible: Starting the Wegovy tablet now does not prevent you from switching to a more effective drug when and if it becomes available. Your prescriber can reassess your treatment at any point.
- Trial data is not real-world data: Phase 2/3 efficacy numbers are averages under controlled conditions. Individual outcomes vary significantly. A drug showing 24% weight loss in a trial may produce 10% in one patient and 30% in another.
- The Wegovy tablet is available now: From five regulated UK providers, from £64/month, with a legitimate clinical assessment process.
How we track the pipeline
We monitor clinical trial registries, MHRA public statements, EMA updates, company press releases and peer-reviewed publications. We update this page when material developments occur. We flag the source and date of each update so you can assess the reliability of what you are reading.
This page covers pipeline drugs relevant to our core focus: oral and tablet-based weight management options for UK patients. For injectable drug pipeline content, we recommend consulting specialist obesity medicine sources.
Get pipeline alerts
We send a notification when any pipeline drug on this page reaches a material regulatory milestone — MHRA submission, approval or confirmed UK launch.
Subscribe to pipeline updates →
Related pages
Frequently asked questions
Which new weight-loss drug is the most effective?
In trials, retatrutide has reported the highest weight loss among the pipeline candidates, ahead of CagriSema and the oral options. Trial figures are averages under controlled conditions and individual results vary. None of the strongest options is UK-licensed yet.
Should I wait for a better drug or start the Wegovy tablet now?
That is a clinical decision for your prescriber. The Wegovy tablet is available now from regulated UK providers, and starting does not prevent switching later if a more effective licensed option arrives. Speak to your prescriber.